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quently observed in these patients1. On average the
neoplastic manifestation occurs 13 years after the diag-
nosis. The simultaneous onset of cancer and SSc, sug-
gesting a possible paraneoplastic origin to the connec-
tive tissue disease, is rarely seen. Even though the litera-
ture reports several cases, there are no classification cri-
teria for paraneoplastic scleroderma, accessing its
incidence hard to estimate. The current paradigm would
require that the scleroderma manifestations regress after
suitable treatment for the underlying cancer, in order to
consider the case as paraneoplastic. This has been ascer-
tained/determined in a number of published reports2-4.
cAse report
A sixty-year-old woman was admitted to the Rheuma-
tology Department for clinical investigation of bilateral
Raynaud’s phenomenon and skin changes that had be-
gun a year before. In the last four months she develo-
ped not only persistent and diffuse hand edema and
progressive thickening of the skin of the fingers, hands,
forearms and face but also sicca syndrome. During the
systematic enquiry, the patient described episodes of
bloody diarrhea, and the loss of six kilograms in weight
within that period of time.
The patient had hypertension and hypothyroidism,
and had been previously submitted to hysterectomy
and bilateral anexectomy for ovarian cysts. During a
colonoscopy performed five years before, a sigmoid co-
lon adenomatous polyp was identified and removed.
The patient worked in a paper factory, had no con-
tact with chemical products and denied smoking habits
as well as alcohol or illicit drugs consumption. At the
time of admission the patient was submitted to treat-
ment with lisinopril, hydrochlorothiazide, levotiroxin,
amitriptilin and oral iron.
The physical examination showed microstomy, skin
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AbstrAct
Occasionally, auto-immune diseases may emerge as pa-
raneoplastic syndromes. This is especially recognized in
the case of polymyositis/dermatomyostis, but it is an
extremely rare event in systemic sclerosis (SSc). The
authors report the case of a sixty-year-old woman who
presented with Raynaud’s phenomenon and rapidly
progressing skin thickness of the forearms, hands and
lower limbs. Patient evaluation revealed a colorectal
carcinoma. The patient was referred to the oncology
department. This concomitance of cancer and SSc with
rapid progression of the latter, suggests that the sclero-
derma might have a paraneoplastic origin. Such an hy-
pothesis deserves consideration in every case as early
diagnosis may be decisive to control the progression of
either disease.
Keywords: Paraneoplastic syndrome; Systemic sclero-
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IntroductIon
Systemic sclerosis (SSc) is a connective tissue disorder
characterized by cutaneous sclerosis with visceral in-
volvement. Its etiology is unclear, but some genetic fac-
tors have been implicated in disease susceptibility and
pattern of clinical manifestations. The pathogenesis,
which is still obscure, includes vascular, inflammatory
and fibrotic processes.
The association of SSc with cancer seems to be much
stronger than mere coincidence. The prevalence of can-
cer in patients with systemic sclerosis has been estima-
ted between 3 and 11%. Lung cancer is the most fre-
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thickening of the upper and lower limbs (distal to the
elbows and knees) and sclerodactyly, with trophic scar
lesions in the fingers and moderate oligoarthritis in the
proximal interphalangeal (PIP) joints of both hands
(Figs. 1 and 2). The modified Rodnan skin thickness
score was 20 (range 0-51). The chest skin was normal.
There were no other remarkable findings on clinical
examination.
Laboratory tests revealed moderate microcytic nor-
mochromic anemia (Hb10.3 g/dl), elevated erythro-
cyte sedimentation rate (45 mm/hour), positive anti-
nuclear antibodies (ANA) (>1/640) and positive anti-
-Scl 70. Tumor markers were negative, except CA 19.9,
which was slightly elevated (78 U/L). The biochemis-
try blood analysis, urinalysis, protein immuno-elec-
trophoresis and thyroid hormone levels were normal.
Chest X-ray and lung function tests were normal.
The nailfold capillaroscopy revealed enlarged capilla-
ries and avascular areas. The patient underwent colo-
noscopy, which revealed an irregular ulcerated lesion,
10 cm from the anal margin, compatible with a neo-
plasm (Fig. 3). The computerized axial tomography
scan of the thorax, abdomen and pelvis and the mag-
netic resonance imaging (MRI) of the pelvis confirmed
the neoplasm diagnosis and revealed the infiltration of
the sacrum and the coccyx. A metastatic nodule in the
iliac bone, and lymphadenopathies in relation to the
neoplastic tissue were also revealed (Fig 4). The neo-
plasm was staged as pT4 N1 M1. The patient was re-
ferred to the Oncology Department and was treated
with radiotherapy. Unfortunately, the treatment was
unsuccessful and the patient died within 4 months,
precluding additional assessment of SSc and the asso-
ciated antibody profile.
FIGure 1. Skin thickness of face, microstomy
FIGure 3. Colonoscopy showing a tumoral mass
FIGure 4. MRI of pelvic region revealing the invasion of the
sacrum and the coccyx by tumoral tissue
FIGure 2. Sclerodactyly, PIP oligoarthritis
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antibodies (ANA) and anti-Scl-70. Although sclero-
derma started after surgical removal of the tumor, a pa-
raneoplastic origin was suggested, since further inves-
tigation revealed metastatic disease in the lung.
Two other reports2,3 described scleroderma manifes-
tations and elevated titers of ANA within a few months
after the first symptoms of the colon adenocarcinoma.
These patients underwent surgery for neoplasm resec-
tion, with subsequent resolution of the scleroderma le-
sions, thus supporting their paraneoplastic origin.
The current classification criteria do not allow dis-
tinction between SSc and the paraneoplastic sclero-
dermiform syndrome.  The diagnosis is obtain on a cli-
nical basis, including the age of onset, the timely asso-
ciation with cancer of symptoms onset and response
to treatment. Paraneoplastic rheumatic syndromes may
coincide or follow the diagnosis of primary malignan-
cy, but could precede the onset of cancer by two years5.
The development of the rheumatic disease is frequen-
tly closely related with the development of cancer5,15. In
fact, there is a symptom recovery and a decrease of the
antibody levels as the tumor tissue disappears or redu-
ces2,3.
Paraneoplastic sclerodermiform syndrome is firstly
associated with a later age of onset, a refractory and
unilateral Raynaud’s phenomenon, and a poor respon-
se to conventional treatment2-5. Secondly it is also con-
nected with a good response to the treatment of the un-
derlying tumour with amelioration of symptoms and
decrease or disappearance of antibody titers, which are
the key to distinguish paraneoplastic from primary
auto-immune SSc6,16.
The presence of antibodies, typical of rheumatic di-
seases, is frequent in the paraneoplastic condition and
delays the diagnosis of the occult neoplasm17.
In a study18 that assessed the prevalence of ANA in
94 patients, with paraneoplastic syndrome of solid tu-
mors, forty patients presented arthritis and twenty four
exhibited Raynaud phenomenon. The study showed
that 22.3% of the patients were ANA positive. The anti-
-extractable nuclear antigen (ENA) antibodies were
even more frequent, existing in 27.7% of the patients.
Until recently, there were no studies reporting the as-
sociation between the antibody profile and a potential
un derlying cancer in scleroderma. Shah and collea-
gues19 showed a close temporal relationship between
the cancer onset in scleroderma and the presence of
anti-RNA polymerase I/III antibodies. The average du-
ration of disease at cancer diagnosis was -1.2 years (ran-
ge – 2 to 1.3 years) and the mean time lapse since Ray-
dIscussIon
We present a clinical case showing a rapidly progres-
sing SSc with a concomitant colorectal carcinoma.
Skin thickening can be found in several diseases
such as systemic sclerosis, eosinophilia-myalgia syn-
drome, eosinophilic fasciitis, graft vs host disease, my-
cosis fungoides, nephogenic systemic fibrosis, prima-
ry biliary fibrosis, primary pulmonary hypertension,
reflex sympathetic dystrophy, scleredema, scleromyxe-
dema, endocrine disorders and amyloidosis. It can also
develop after exposure to chemotherapeutic agents and
organic solvents or in patients with an underlying can-
cer. All these conditions, except for SSc and paraneo-
plastic sclerodermiform syndrome, were excluded from
this clinical case.
It is known that auto-immune diseases can be trig-
gered by tumor development, commonly referred as
paraneoplastic syndromes. These can emerge after the
tumor or metastases onset, simultaneously to the neo-
plasm diagnosis or they can be the cancer’s early ma-
nifestation5,6.
The underlying mechanisms may include the relea-
se of active mediators by the cancer cells, such as the
transforming growth factor beta, resulting in sclero-
derma skin changes7. Another hypothesis is based in an
auto-immune reaction triggered by the expression by
tumor cell of antigens that cross-react with those im-
plicated in the primary auto-immune disease. Other
authors argue that the cancer and the rheumatic con-
dition are a consequence of similar exogenous stimuli,
such as a viral infection or drug administration8.
Polymyositis/dermatomyostis is the most reported
rheumatic paraneoplastic syndrome. Other common-
ly referred associations include vasculitis, polyarthritis
and hypertrophic osteoarthropathy5. SSc is rarely des-
cribed as a paraneoplastic syndrome, with only a few
reports in the literature. The associated neoplasms in
these reports include not only breast9,10, lung11, ovary,
oral cavity and pharynx cancer but also non-Hodgkin
lymphomas12,13. The association with colorectal carci-
noma is not well documented. Orphanos et al14 des-
cribed the case of a 56-year-old man, diagnosed with
an adenocarcinoma of the rectum, who developed te-
langiectasias and small cheek skin lesions 3 months 
after the surgery. The patient sought medical help 5
years after surgery and, at the time, presented skin thic-
kening, distal to the metacarpophalangeal joints, atro -
phic skin lesions of the face and dyspnea. Laboratory
tests showed him to be positive for both anti-nuclear
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naud onset was 0.25 years. In 66,6% of these patients,
cancer diagnosis closely preceded scleroderma onset.
However, the number of patients was small (23 patients
recruited, 6 with anti-RNA polymerase I/III antibodies).
Regrettably, the short time of survival did not allow
us to assess the possible effect of radiotherapy on the
scleroderma and the antibody profile.
The possibility that a threatening disease such as SSc
could be resolved or improved by the treatment of a
triggering neoplasm lead us to publish this case, ho-
ping to stimulate the consideration of the paraneo-
plastic hypothesis in patients who have SSc. Moreover,
this report emphasizes that classification criteria are ne-
cessary to estimate the real prevalence of paraneoplas-
tic scleroderma.
The clinical procedures in these patients should have
in mind the most frequent neoplasms associated with
this disease. In patients’ follow-up, the surveillance of
signs, symptoms and immunological profile may help
to fully elucidate the diagnosis and assess the disease
progression. 
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